Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Giving Gefitinib before surgery may make the tumor smaller and reduce
the amount of normal tissue that needs to be removed.
PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with
stage IIIA non-small cell lung cancer.